A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2017-10-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of RNS60 in patients
with Amyotrophic lateral sclerosis (ALS). Investigators will also measure the impact of RNS60
on several markers of neuro-inflammation, measured by blood biomarkers and positron emission
tomography (PET) imaging.